Home › Funds › CONWAY CAPITAL MANAGEMENT, INC. › BSX
CONWAY CAPITAL MANAGEMENT, INC. position in BSX
BOSTON SCIENTIFIC CORP · Health Care
CONWAY CAPITAL MANAGEMENT, INC. reported holding 26,600 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$1.2M, representing 0.49% of its reported portfolio and ranking #24 among its reported holdings. CONWAY CAPITAL MANAGEMENT, INC. has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How CONWAY CAPITAL MANAGEMENT, INC.'s BSX position evolved
CONWAY CAPITAL MANAGEMENT, INC. first disclosed a stake in BSX in Q3 2023 at 34,015 shares (US$1.8M). The position peaked in Q2 2025 at 29,645 shares, worth US$3.2M. Across 13 filings, CONWAY CAPITAL MANAGEMENT, INC. increased the stake 0 time(s), trimmed it 7 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 26,600 shares valued at US$1.2M — a reduction of -2,150 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 34.02K | $1.80M | New |
| Q4 2023 | 31.93K | $1.85M | Reduce |
| Q1 2024 | 31.93K | $2.19M | Hold |
| Q2 2024 | 31.93K | $2.46M | Hold |
| Q3 2024 | 31.93K | $2.68M | Hold |
| Q4 2024 | 31.93K | $2.85M | Hold |
| Q1 2025 | 31.37K | $3.16M | Reduce |
| Q2 2025 | 29.64K | $3.18M | Reduce |
| Q3 2025 | 29.64K | $2.89M | Hold |
| Q4 2025 | 29.39K | $2.80M | Reduce |
| Q1 2026 | 28.90K | $1.81M | Reduce |
| Q2 2026 | 28.75K | $1.23M | Reduce |
| Q3 2026 | 26.60K | $1.16M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BSX and 13F data
BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 18 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.56B), MFS Investment Management (US$2.29B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BSX
- PRIMECAP MANAGEMENT CO/CA/ 58.62M sh · $2.56B · Q3 2026
- MFS Investment Management 43.05M sh · $2.29B · Q3 2026
- D. E. Shaw & Co 27.27M sh · $1.16B · Q2 2026
- Janus Henderson Group 16.50M sh · $1.04B · Q1 2026
- Arrowstreet Capital 23.29M sh · $994.18M · Q2 2026
More on CONWAY CAPITAL MANAGEMENT, INC.
FAQ
How long has CONWAY CAPITAL MANAGEMENT, INC. held BSX?
CONWAY CAPITAL MANAGEMENT, INC. has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is CONWAY CAPITAL MANAGEMENT, INC.'s current position in BSX?
As of Q3 2026, CONWAY CAPITAL MANAGEMENT, INC. holds 26.60K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $1.16M, representing 0.49% of its reported portfolio and ranking #24.
Has CONWAY CAPITAL MANAGEMENT, INC. been buying or selling BSX?
In the latest 13F filing (Q3 2026), CONWAY CAPITAL MANAGEMENT, INC. reduced its position in BSX. The position peaked in Q2 2025 at 29.64K shares.
Which other funds hold BSX?
Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, MFS Investment Management, D. E. Shaw & Co, among 18 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.